TICKERNERD
Menu
MXCTMXCTHealthcare · Medical Devices

MXCT Stock Forecast: MaxCyte, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.16
−2.52% on the day

The 6 Wall Street analysts covering MaxCyte, Inc. hold a median 12-month price target of $4.5 — +287.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 11 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$122.8M
Ticker Nerd rank
75 / 100
Median analyst target
$4.50
Analysts covering
6
Revenue$7.3M−14.5% y/y
Operating income−$10.2M
Net income−$8.9M
Free cash flow−$4.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.9%
1M
−6.5%
YTD
−25.2%
1Y
−21.6%
From 52W high
−36.6%
From 52W low
+71.6%
$0.68
$1.83
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MXCT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MaxCyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
75 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
90
Issuance
81
Accruals
77
Size
73
Value
50
Revisions
50
Quality
49
Volatility
44
Momentum
38

Growth (90): Sales and profits are climbing, and climbing faster than before.

Momentum (38): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MXCT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MXCT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26MXCTHigh $5.00Median $4.50Low $2.43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
5 Buy1 Hold0 Sell
Low $2.43Median $4.50High $5.00

The green dot is the last close — the median target sits +287.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Mar 2026Craig-HallumMaintainsBuy$7.00 → $5.00
11 Aug 2025BTIGDowngradeNeutral—
7 Aug 2025William BlairDowngradeMarket Perform—
22 July 2025Stephens & Co.AssumesOverweight$6.00
12 Mar 2025StifelMaintainsBuy—
23 Apr 2024Stephens & Co.ReiteratesOverweight—
13 Mar 2024BTIGMaintainsBuy—
13 Mar 2024Stephens & Co.ReiteratesOverweight—
29 Nov 2023Craig-HallumInitiatesBuy—
5 Oct 2023Stephens & Co.ReiteratesOverweight—
28 Mar 2023Stephens & Co.ReiteratesOverweight—
15 Aug 2022BTIGMaintainsBuy—
24 Aug 2021BTIGInitiatesBuy—
24 Aug 2021Cowen & Co.InitiatesOutperform—
24 Aug 2021Stephens & Co.InitiatesOverweight—
24 Aug 2021StifelInitiatesBuy—
24 Aug 2021William BlairInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MXCT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MXCT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, MaxCyte, Inc. returned −21.6% against +17.5% for the S&P 500, dividends included.

MXCT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26MXCTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MXCT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

MaxCyte, Inc. (MXCT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.9×

Cheaper than 87% of US stocks

Price / sales
4.0×

Cheaper than 31% of US stocks

Price / book
0.8×

Cheaper than 79% of US stocks

EV / EBITDA
−1.1×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
−14.5%

Higher than 13% of US stocks

Earnings growth (YoY)
−14.5%

Higher than 23% of US stocks

Gross margin
77.0%

Higher than 89% of US stocks

Operating margin
−140.7%

Higher than 12% of US stocks

Net margin
−114.8%

Higher than 5% of US stocks

Returns & dividend
Return on equity
−20.4%

Higher than 31% of US stocks

Return on assets
−10.6%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MaxCyte, Inc. (MXCT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MaxCyte, Inc. has a market value of $122.8M and an enterprise value of $34.4M.

  • Revenue in the twelve months to 30 June 2026: $31.1M. The latest quarter shrank 14.5% year on year.

  • Net income over the same four quarters: −$35.6M, a −114.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.33.

  • Free cash flow in the twelve months to 30 June 2026: −$23.8M.

  • Shares outstanding: 106.1M.

  • Trailing P/E: −2.9×; forward P/E: −4.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • MaxCyte, Inc. employs 91 people — $341K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

MXCT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
MXCTMaxCyte, Inc.$122.8M
75
QTRXQuanterix Corp.$120.6M
29
APYXApyx Medical Corp.$118.9M
63
OWLTOwlet, Inc.$136.0M
34
INGNInogen, Inc.$144.6M
82
MBOTMicrobot Medical, Inc.$97.4M
15
LUCDLucid Diagnostics, Inc.$159.0M
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MaxCyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MXCT news & analysis

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 11 Sept 2026neutral

MaxCyte reported that its Compensation Committee granted inducement awards to Sidharth Kapileshwar in connection with his start as Senior Vice-President, Chief Corporate Development Officer. The awards, consisting of stock options for 220,000 shares and a restricted stock unit award for 110,000 shares, were granted under the 2026 Inducement Plan on August 31, 2026, per Nasdaq Listing Rule 5635(c)(4).

Why it matters — MXCT watchers would care because this signals the company's executive hiring incentive structure and a new corporate development leadership addition.

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

GlobeNewsWire · 19 Aug 2026positive

MaxCyte announced the launch of CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays, available through its SeQure™ service. The assays are designed to provide sensitive identification of off-target sites for adenine and cytosine base editors in genome editing characterization.

Why it matters — The launch expands MaxCyte's SeQure™ service offering by addressing a key gap in genome editing off-target assessment, potentially strengthening its platform for cell therapy development.

MaxCyte Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026neutral

MaxCyte reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, due to lower license revenue, instrument placement timing, and prior-year processing assembly purchases. Management said the quarter exceeded its expectations and represented progress toward stabilizing the business before returning to growth in the second half of the year.

Why it matters — The revenue decline and management's outlook on stabilization and second-half growth are directly relevant to MXCT watchers tracking the company's near-term trajectory.

MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

MaxCyte, Inc. held its Q2 2026 earnings call, during which management discussed the company's financial results and operational performance for the quarter.

Why it matters — This earnings call provides MXCT investors and analysts with direct commentary from management on the company's recent financial health and strategic direction.

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 12 Aug 2026positive

MaxCyte, Inc. reported a second-quarter loss of $0.08 per share, smaller than the Zacks Consensus Estimate of a $0.12 loss and an improvement from the $0.12 loss per share in the prior-year quarter. The company also beat revenue estimates.

Why it matters — A narrower-than-expected loss and revenue beat indicate the company's quarterly performance came in better than analysts had projected.

FAQ

Frequently asked questions about MXCT stock

What is the MXCT stock price forecast for 2026-2027?

The 6 Wall Street analysts covering MaxCyte, Inc. have a median 12-month price target of $4.5, with estimates ranging from $2.43 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MXCT stock a buy right now?

Of the 6 analysts covering MaxCyte, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MaxCyte, Inc. 75 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MXCT?

As at 11 Sept 2026, MaxCyte, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (90 of 100).

Will MXCT stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +287.9% from the last close, and Ticker Nerd's factor model ranks MaxCyte, Inc. 75 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MXCT stock forecast for 2030?

No analyst covering MaxCyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MXCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.43 to $5 over the next 12 months.

How has MXCT stock performed over the past year?

MaxCyte, Inc. returned -21.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MaxCyte, Inc. do?

MaxCyte, Inc. is a life sciences tools company focused on cell engineering for cell and gene therapy development.

What is the latest news on MXCT?

The most recent item we track (GlobeNewsWire, 11 Sept 2026): "MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". MaxCyte reported that its Compensation Committee granted inducement awards to Sidharth Kapileshwar in connection with his start as Senior Vice-President, Chief Corporate Development Officer. The awards, consisting of stock options for 220,000 shares and a restricted stock unit award for 110,000 shares, were granted under the 2026 Inducement Plan on August 31, 2026, per Nasdaq Listing Rule 5635(c)(4).

Company

About MaxCyte, Inc.

MaxCyte, Inc. is a life sciences tools company focused on cell engineering for cell and gene therapy development. MaxCyte designs and commercializes non-viral flow electroporation systems, proprietary processing assemblies, and consumables that help biotechnology and pharmaceutical companies introduce biological cargo into cells with precision and consistency. Its platform is used across drug discovery, translational research, and biomanufacturing, supporting applications in gene editing, immuno-oncology, and other advanced cell-based medicines. The company also offers licensing arrangements tied to partner programs, making its technology part of broader therapeutic development workflows. Headquartered in Rockville, Maryland, MaxCyte serves a global customer base involved in next-generation cell therapeutics and related research.

CEO Mr. Maher Masoud · 91 employees · United States · https://www.maxcyte.com